New cancer drug copycat tested on healthy volunteers

NCT ID NCT07299955

Summary

This is an early, first-in-human study to see how a new, similar version of the cancer drug Herceptin Hylecta (called Bmab3000) behaves in the body. It will involve 150 healthy male volunteers who will receive a single injection and be monitored for about four months. The main goal is to compare how the two drugs are processed by the body and to check for safety and immune reactions.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY MALE PARTICIPANTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.